{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T19:02:36Z","timestamp":1774897356325,"version":"3.50.1"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,9,14]],"date-time":"2018-09-14T00:00:00Z","timestamp":1536883200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100011110","name":"UCB","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011110","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s13075-018-1707-8","type":"journal-article","created":{"date-parts":[[2018,9,14]],"date-time":"2018-09-14T04:33:35Z","timestamp":1536899615000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["A single determination of C-reactive protein does not suffice to declare a patient with a diagnosis of axial spondyloarthritis \u2018CRP-negative\u2019"],"prefix":"10.1186","volume":"20","author":[{"given":"Robert","family":"Landew\u00e9","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tommi","family":"Nurminen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Owen","family":"Davies","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominique","family":"Baeten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,9,14]]},"reference":[{"issue":"6","key":"1707_CR1","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1136\/ard.2009.108217","volume":"68","author":"M Rudwaleit","year":"2009","unstructured":"Rudwaleit M, Landew\u00e9 R, van der Heijde D, et al. The development of assessment of SpondyloArthritis International Society classification criteria for axial spondyloarthritis (part I): classification of paper patients by expert opinion including uncertainty appraisal. Ann Rheum Dis. 2009;68(6):770\u20136.","journal-title":"Ann Rheum Dis"},{"key":"1707_CR2","doi-asserted-by":"crossref","unstructured":"Sieper J, van der Heijde D, Elewaut D et al. Disease burden is comparable in patients with non-radiographic axial spondyloarthritis and ankylosing spondylitis [abstract]. American College of Rheumatology 2012. November 9\u201314; Washington, DC. Abstract no. 1361.","DOI":"10.1136\/annrheumdis-2012-eular.1949"},{"issue":"Suppl 1","key":"1707_CR3","doi-asserted-by":"publisher","first-page":"e000053","DOI":"10.1136\/rmdopen-2015-000053","volume":"1","author":"X Baraliakos","year":"2015","unstructured":"Baraliakos X, Braun J. Non-radiographic axial spondyloarthritis and ankylosing spondylitis: what are the similarities and differences? RMD Open. 2015;1(Suppl 1):e000053.","journal-title":"RMD Open"},{"issue":"Suppl 2","key":"1707_CR4","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1136\/annrheumdis-2016-eular.6388","volume":"75","author":"J Sieper","year":"2016","unstructured":"Sieper J. SP0108\u00a0Different approaches to drug approval by EMA and FDA\u2014the example of non-radiographic axial spondyloarthritis. Ann Rheum Dis. 2016;75(Suppl 2):27.","journal-title":"Ann Rheum Dis"},{"key":"1707_CR5","unstructured":"U.S. Food and Drug Administration. Center for Drug Evaluation and Research. Cimzia (2008). https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/125160s270lbl.pdf . Accessed 19 June 2017."},{"key":"1707_CR6","unstructured":"U.S. Food and Drug Administration. Center for Drug Evaluation and Research. Simponi (2009). https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/125289s0064lbl.pdf . Accessed 19 June 2017."},{"key":"1707_CR7","unstructured":"U.S. Food and Drug Administration. Center for Drug Evaluation and Research. Enbrel (2003). https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2003\/103795_S5097_ENBREL.pdf . Accessed 19 June 2017."},{"key":"1707_CR8","unstructured":"U.S. Food and Drug Administration. Center for Drug Evaluation and Research. Remicade (2004). https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/103772s5370lbl.pdf . Accessed 19 June 2017."},{"issue":"9","key":"1707_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta20090","volume":"20","author":"M Corbett","year":"2016","unstructured":"Corbett M, Jhuti G, Rice S, et al. Tumour necrosis factor-\u03b1 inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis: a systematic review and economic evaluation. Health Technol Assess. 2016;20(9):1\u2013334.","journal-title":"Health Technol Assess"},{"key":"1707_CR10","unstructured":"European Medicine\u2019s Agency. Positive recommendations of Committee for Medicinal Products for Human Use (CHMP) on extensions of therapeutic indications for Humira (21 June 2012). http:\/\/www.emea.europa.eu\/ema\/pages\/includes\/document\/open_document.jsp?webContentId=WC500129074 . Accessed 13 June 2017."},{"key":"1707_CR11","unstructured":"European Medicine\u2019s Agency. Positive recommendations of Committee for Medicinal Products for Human Use (CHMP) on extensions of therapeutic indications for Enbrel (26 June 2014). http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Assessment_Report_-_Variation\/human\/000262\/WC500172150.pdf . Accessed 13 June 2017."},{"key":"1707_CR12","unstructured":"European Medicine\u2019s Agency. Summary of Product Characteristics for Cimzia (16 May 2014). http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/001037\/WC500069763.pdf . Accessed 13 June 2017."},{"key":"1707_CR13","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.2147\/DDDT.S107587","volume":"10","author":"E Toussirot","year":"2016","unstructured":"Toussirot E, Vauchy C, Binda D, Michel F. Golimumab in radiographic and nonradiographic axial spondyloarthritis: a review of clinical trials. Drug Des Devel Ther. 2016;10:2087\u201394.","journal-title":"Drug Des Devel Ther"},{"issue":"6","key":"1707_CR14","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1136\/annrheumdis-2012-201766","volume":"72","author":"J Sieper","year":"2013","unstructured":"Sieper J, van der Heijde D, Dougados M, et al. Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1). Ann Rheum Dis. 2013;72(6):815\u201322.","journal-title":"Ann Rheum Dis"},{"key":"1707_CR15","doi-asserted-by":"crossref","unstructured":"Ward MM, Deodhar A, Akl EA, et al. American College of Rheumatology\/Spondylitis Association of America\/Spondyloarthritis research and treatment network 2015 recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis. Arthritis Rheumatol. 2016;68(2):282\u201398.","DOI":"10.1002\/art.39298"},{"key":"1707_CR16","unstructured":"National Institute for Health and Care Excellence. TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis (TA383). https:\/\/www.nice.org.uk\/guidance\/ta383 . Accessed 6 Mar 2018."},{"issue":"9","key":"1707_CR17","doi-asserted-by":"publisher","first-page":"2369","DOI":"10.1002\/art.39225","volume":"67","author":"D Poddubnyy","year":"2015","unstructured":"Poddubnyy D, Haibel H, Braun J, Rudwaleit M, Sieper J. Brief report: clinical course over two years in patients with early nonradiographic axial spondyloarthritis and patients with ankylosing spondylitis not treated with tumor necrosis factor blockers: results from the German spondyloarthritis inception cohort. Arthritis Rheumatol. 2015;67(9):2369\u201375.","journal-title":"Arthritis Rheumatol."},{"issue":"1","key":"1707_CR18","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1136\/annrheumdis-2013-204231","volume":"73","author":"R Landew\u00e9","year":"2014","unstructured":"Landew\u00e9 R, Braun J, Deodhar A, et al. Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled phase 3 study. Ann Rheum Dis. 2014;73(1):39\u201347.","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"1707_CR19","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1093\/rheumatology\/kex174","volume":"56","author":"D\u00e9sir\u00e9e van der Heijde","year":"2017","unstructured":"van der Heijde D, Dougados M, Landew\u00e9 R, et al. Sustained efficacy, safety and patient-reported outcomes of certolizumab pegol in axial spondyloarthritis: 4-year outcomes from RAPID-axSpA. Rheumatology (Oxford). 2017:kex174. https:\/\/doi.org\/10.1093\/rheumatology\/kex174 .","journal-title":"Rheumatology"},{"key":"1707_CR20","volume-title":"Linear mixed models for longitudinal data","author":"G Verbeke","year":"2000","unstructured":"Verbeke G, Molenberghs G. Linear mixed models for longitudinal data. New York: Springer-Verlag; 2000."},{"issue":"7","key":"1707_CR21","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1093\/rheumatology\/kex081","volume":"56","author":"Xenofon Baraliakos","year":"2017","unstructured":"Baraliakos X, Sieper J, Chen S, Pangan AL, Anderson J. Non-radiographic axial spondyloarthritis patients without initial evidence of inflammation may develop objective inflammation over time. Rheumatology (Oxford). 2017:kex081. https:\/\/doi.org\/10.1093\/rheumatology\/kex081 .","journal-title":"Rheumatology"}],"container-title":["Arthritis Research & Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-018-1707-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13075-018-1707-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-018-1707-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T06:55:52Z","timestamp":1751871352000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-018-1707-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,14]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["1707"],"URL":"https:\/\/doi.org\/10.1186\/s13075-018-1707-8","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,14]]},"assertion":[{"value":"19 March 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study protocol, amendments, and subject informed consent were reviewed by a national, regional, or Independent Ethics Committee (IEC) or Institutional Review Board (IRB). This study was conducted in accordance with the current version of the applicable regulatory and International Conference on Harmonisation (ICH)-Good Clinical Practice (GCP) requirements, the ethical principles that have their origin in the principles of the Declaration of Helsinki, and the local laws of the countries involved. Informed consent was obtained from subjects and documented in accordance with local regulations, ICH-GCP requirements, and the ethical principles that have their origin in the principles of the Declaration of Helsinki.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"RL has received consultancy fees and\/or research grants and\/or speaker\u2019s bureau from AbbVie, Ablynx, Amgen, AstraZeneca, Bristol-Myers Squibb, Centocor, GlaxoSmithKline, Novartis, Merck, Pfizer, Roche, Schering-Plough, and UCB Pharma. TN is an employee of UCB Pharma. OD is an employee and stockholder of UCB Pharma. DB has acted as an advisor and\/or provided research collaboration for AbbVie, Bristol-Myers Squibb, Boehringer Ingelheim, Eli Lilly, Janssen, MSD, Novartis, Pfizer, Roche, and UCB Pharma, and is an employee of UCB Pharma.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"209"}}